Safe methadone induction and stabilization report of an expert panel

Journal of Addiction Medicine

Volumn 7, Issue 6, 2013, Pages 377-386

  Baxter Sr , Louis E ^a   Campbell, Anthony ^b   DeShields, Michael ^c   Levounis, Petros ^d   Martin, Judith A ^e   McNicholas, Laura ^f   Payte, J T ^g   Salsitz, Edwin A ^h   Taylor, Trusandra ⁱ   Wilford, Bonnie B ^j  

^a American Society of Addiction Medicine   (United States)

^b U S PUBLIC HEALTH SERVICE   (United States)

^c Medical Affairs ^*  (United States)

^d Mental Health Care   (United States)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h BETH ISRAEL MEDICAL CENTER   (United States)

ⁱ JEVS Human Services   (United States)

^j JBS International Inc   (United States)

more..

Author keywords

Methadone; Methadone dosing; Methadone induction; Methadone mortality; Methadone overdose; Opioid agonist treatment

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CENTRAL DEPRESSANT AGENT; HYPNOTIC AGENT; METHADONE; OPIATE; SEDATIVE AGENT;

ASPIRATION PNEUMONIA; CONSTIPATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EUPHORIA; HEART ARRHYTHMIA; HUMAN; HYPOXIA; INFORMED CONSENT; INSOMNIA; LUNG EDEMA; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN; WITHDRAWAL SYNDROME;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG OVERDOSE; HUMANS; INDUCTION CHEMOTHERAPY; MEDICATION THERAPY MANAGEMENT; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT EDUCATION AS TOPIC; RISK ADJUSTMENT;

EID: 84887977595     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/01.ADM.0000435321.39251.d7     Document Type: Review

References (89)

1. Albion C, Shkrum M, Cairns J. Contributing factors to methadone-related deaths in Ontario. Am J Forensic Med Pathol 2010;31(4):313-319
2. Anderson IB,Kearney TE. Use ofmethadone. West JMed 2000;172(1):43-46
3. Appel PW, Joseph H, Richman BL. Causes and rates of death among methadone maintenance patients before and after the onset of the HIV/AIDS epidemic. Mt Sinai J Med 2000;67(5/6):444-451
4. Bao Y, Liu Z, Epstein D, et al. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse. 2009;35(1):28-33
5. Batki SL, ed. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs (Treatment Improvement Protocol [TIP] No. 43). Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 2005. DHHS publication no. [SMA] 05-4048
6. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009;104(1-2):73-77
7. Bell J, Kimber J, LintzerisN, et al. NationalDrug Strategy: Clinical Guidelines for the Use of Naltrexone in the Management of Opioid Dependence. Canberra, Australia: Department of Health and Ageing, 2003
8. Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Saf 2000;22(3):179-190
9. Brown R, Kraus C, Flemina M, et al. Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgrad Med J 2004;80:654-659
10. Caplehorn JR, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust 1991;154(3):195-199. [Erratum in Med J Aust 1993;159(9):640]
11. Caplehorn JR, Drummer OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health 2002;26(4):358-623
12. Center for Substance Abuse Treatment (CSAT). Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs (Treatment Improvement Protocol [TIP] Series 43). HHS Publication No. (SMA) 08-4214. Rockville, MD: CSAT, Substance Abuse and Mental Health Services Administration, 2008
13. Christensen AJ, Howren MB, Hillis SL, et al. Patient and physician beliefs about control over health: association of symmetrical beliefs with medication regimen adherence. J Gen Intern Med. 2010;25(5):397- 402
14. College of Physicians and Surgeons of Ontario. Methadone for Pain Guidelines. Toronto, ON: College of Physicians and Surgeons of Ontario, 2004
15. College of Physicians and Surgeons of Ontario. Methadone Maintenance Guidelines. Toronto, ON: College of Physicians and Surgeons of Ontario, 2005
16. Davoli M, Bargagli AM, Perucci CA, et al. for the VEdeTTE Study Group. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007;102(12):1954-1959
17. Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA 1988;260:3025-3029
18. Drummer OH, Opeskin K. Methadone toxicity causing death in ten subjects starting on a methadone maintenance program. Am J Forensic Med Pathol 1992;13(4):346-350
19. Eap CB, Bertschy G, Finkbeiner T, et al. High inter-individual variability of methadone enantiomer blood levels to dose ratios [letter]. Arch Gen Psychiatry 1988;55:89-90
20. Eap CB, Bourquin M, Martin JL, et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000;6(11):47-54
21. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokin 2002;31(14):1153-1193
22. Eap CB, D́eglon J-J, Baumann P. Pharmacokinetics and pharmacogenetics of methadone: clinical relevance. Heroin Add Rel Clin Probl 1999;1(1): 19-34
23. Food and Drug Administration. Death, narcotic overdose, and serious cardiac arrhythmias: information for healthcare professionals on methadone. J Pain Palliat Care Pharmacother 2007;21(2):69-71
24. Foster DJR, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999;47:403-412
25. Gagajewski A, Apple FS. Methadone-related deaths in Hennepin County, Minnesota: 1999-2002. J Forensic Sci 2003;48(3):1-4
26. Gearing FR, Schweitzer MD. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. Am J Epidemiol 1974;100:101-111
27. Gibson A, Degenhardt L, Mattick RP, et al. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008;103:462-468
28. Goldberger BA, Maxwell JC, Campbell A, Wilford BB. Uniform Standards and Case Definitions for Classifying Methadone-Related Deaths: Recommendations by a SAMHSA Consensus Panel. J Addict Dis 2013;32(3):231-243
29. Government Accountability Office. Methadone-Associated Overdose Deaths: Factors contributing to Increased Deaths and Efforts to Prevent Them (GAO-09-341). Washington, DC: Government Accountability Office, 2009
30. Gronbladh L, Ohland LS, Gunne LM. Mortality in heroin addiction: impact of methadone. Acta Psychiatr Scand 1990;82:223-227
31. Hamilton SP, Nunes EV, Janal M, et al. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict 2000;9(1):63-69
32. Harding-Pink D. Methadone: one person's maintenance dose is another's poison. Lancet 1993;341(8846):665-666
33. Herrlin K, Segerdahl M, Gustafsson LL, et al. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000;356(9247):2069-2070
34. Inturrisi CE, Verebely K. The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther 1972;13(5) (pt 1):633-637
35. Joseph H, Woods JS, eds. Methadone Treatment Works: A Compendium for Methadone Maintenance Treatment. CDRWG Monograph Series #2. Albany, NY: Chemical Dependency Research Working Group, New York State Office of Alcoholism and Substance Abuse Services, 1994
36. Karch SB, Stephens BG. Toxicology and pathology of deaths related to methadone: retrospective review. West J Med 2000;172(1):11-14
37. Kauffman J. Dosage Induction With Methadone in the OTP. New York, NY: American Association for the Treatment of Opioid Dependence Inc, 2008
38. Kreek MJ. A personal retrospective and prospective viewpoint. In: Parrino MW, ed. State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1993:133-143
39. Liang SY, Yates P, Edwards H, et al. Factors influencing opioid-taking self-efficacy and analgesic adherence in Taiwanese outpatients with cancer. Psychooncology 2008;17(11):1100-1107
40. Mallinckrodt Inc. Methadose ® Oral Tablets (Methadone hydrochloride tablets USP; 5, 10, 40 mg) [package insert]. St Louis, MO: Mallinckrodt Inc, 1995
41. Mallinckrodt Inc. Methadose ® Oral Concentrate (Methadone hydrochloride oral concentrate USP) [package insert]. St Louis, MO: Mallinckrodt Inc, 2000
42. Marsch LA. The efficacy ofmethadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998;93(4):515-532
43. Martin J. PCSS-M Guidance: Opioid Treatment Program Methadone Induction Dosing. Rockville, MD: Substance Abuse Mental Health Services Administration, 2010
44. Martin JA; for the CSAT Expert Panel on Cardiac Effects of Methadone. QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. J Addict Dis 2011;30(4)283-306
45. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002209
46. Maxwell JC. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev 2011;30(3):264-270
47. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010;1:4-16
48. Medicines and Healthcare Products Regulatory Agency. Current Problems in Pharmacovigilance. Vol 31. London, England: Medicines and Healthcare Products Regulatory Agency, 2006
49. Mikolaenko I, Robinson A, Davis GG. A review of methadone deaths in Jefferson County, Alabama. Am J Forensic Med Pathol 2002;23(3): 299-304
50. Modesto-Lowe V, Brooks D, Petry N. Methadone deaths: risk factors in pain and addicted populations. J Gen Intern Med 2010;9:898
51. Nakamura K, Hachey DL, Kreek MJ, et al. Quantitation of methadone enantiomers in humans using stable isotope-labeled [2H3]-, [2H5]-, and [2H8]methadone. J Pharm Sci 1982;71(1):40-43
52. National Drug Intelligence Center. Methadone Diversion, Abuse and Misuse: Deaths Increasing at Alarming Rate. Johnstown, PA: Drug Enforcement Administration, US Department of Justice, 2007. No. 2007-Q0317-001
53. Parran T. PCCS-M Guidance: Methadone Dosing for Pain and Equianalgesic Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2010
54. Patanwala AE, Duby J, Waters D, Erstad BL. Opioid conversions in acute care. Ann Pharmacother 2007;41:255-267
55. Paulozzi LJ, Annest JL. Unintentional poisoning deaths - United States, 1999-2004. MMWR 2007;56:93-96
56. Paulozzi LJ, Logan JE, Hall AJ, McKinstry E, Kaplan JA, Crosby AE. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction 2009;104(9):1541-1548
57. Paulozzi LJ, Weisler RH, Patkar AA. A national epidemic of unintentional prescription opioid overdose deaths: how physicians can help control it. J Clin Psychiatry 2011;72(5):589-592
58. Payte JT. A brief history of methadone in the treatment of opioid dependence: a personal perspective. J Psychoactive Drugs 1991;23(2):103-107
59. Payte JT, Khuri ET, Joseph H, et al. The Methadone Maintained Patient and the Treatment of Pain. CDRWG Monograph #2. Albany, NY: Chemical Dependency Research Working Group, The New York State Office of Alcoholism and Substance Abuse Services, 1994:35-40
60. Payte JT, Zweben JE. Opioid maintenance therapies. In: Graham AW, Schultz TK, Mayo-Smith MF, et al., eds. Principles of Addiction Medicine. 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003;751-766
61. Piercefield E, Archer P, Kemp P, et al. Increase in unintentional medication overdose deaths-Oklahoma, 1994-2006. Am J Prev Med 2010;39(4):357-363
62. Preston K, Umbricht A, Epstein D. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry 2000;57(4):395-404
63. Repchinsky C, ed. Compendium of Pharmaceutical and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa, ON: Canadian Pharmacists Association, 2003
64. Robinson AE, Williams FM. The distribution of methadone in man. J Pharm Pharmacol 1971;23:353-358
65. Roxane Laboratories. Dolophine ® Hydrochloride (Methadone Hydrochloride Injection, USP) [package insert].Manufactured by Eli Lilly and Company. Columbus, OH: Roxane Laboratories Inc, 1995
66. Roxane Laboratories. Methadone Hydrochloride IntensolTM (Oral Concentrate, USP 10 mg/mL) [package insert]. Columbus, OH: Roxane Laboratories Inc, 1998
67. Roxane Laboratories. Methadone Hydrochloride Tablets USP [package insert]. Columbus, OH: Roxane Laboratories Inc, 2006
68. Shah N, Lathrop SL, Landen MG. Unintentional methadone-related overdose deaths in New Mexico (USA) and implications for surveillance, 1998-2002. Addiction 2005;100:176-188
69. Shields LB, Hunsaker JC, Corey TS, et al. Methadone toxicity fatalities: a review of medical examiner cases in a large metropolitan area. J ForensicSci 2007;52(6):1389-1395
70. Srivastava A, Kahan M. Methadone induction doses: are our current practices safe? J Addict Dis 2006;25(3):5-13
71. Stephenson DK, ed. Guidelines for Physicians Working in California Opioid Treatment Programs. San Francisco, CA: California Society of Addiction Medicine, 2008
72. Stine SM, Meandzija B, Kosten TR. Pharmacologic therapies for opioid addiction. In: Graham AW, Schultz TK, Mayo-Smith MF, et al., eds. Principles of Addiction Medicine. 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine, 2003;735-748
73. Substance Abuse and Mental Health Services Administration. Methadone Mortality: Report of a National Assessment. Appendix 4: Past Investigations of Methadone-Associated Mortality. Rockville, MD: Department of Health and Human Services, 2003
74. Substance Abuse and Mental Health Services Administration. Methadone- Associated Mortality: Report of a National Assessment, May 2003. Rockville, MD: Department of Health and Human Services, 2004a
75. Substance Abuse and Mental Health Services Administration. Treatment of Persons With Co-occurring Disorders. Treatment Improvement Protocol (TIP) Series 42. Rockville, MD: Department of Health and Human Services, 2004b. HHS publication no. (SMA) 08-3992
76. Substance Abuse and Mental Health Services Administration. Guidelines for the Accreditation of Opioid Treatment Programs. Revised. Rockville, MD: Department of Health and Human Services, 2007a
77. Substance Abuse and Mental Health Services Administration. Methadone Mortality: A Reassessment - Report of the Meeting and Follow-up Activities, July 2007. Rockville, MD: Department of Health and Human Services, 2007b
78. Substance Abuse and Mental Health Services Administration. Emergingissues in the use of methadone. Substance Abuse Treatment Advisory. Rockville, MD: Department of Health and Human Services, 2009. HHSpublication no. [SMA] 09-4368
79. Substance Abuse and Mental Health Services Administration (SAMHSA). Medication-Assisted Treatment for Opioid Addiction in Opioid TreatmentPrograms. Treatment Improvement Protocol (TIP) Series 43. HHS Publication No (SMA) 08-4214. Rockville, Maryland, 2010
80. Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit. HHS Publication No. (SMA)13-4742. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013
81. Tarumi Y, Pereira J, Watanabe S. Methadone and fluconazole: respiratory depression by drug interaction. J Pain Symptom Manage 2002;23(2):148- 153
82. Udell JA, Redelmeier DA. Patient preferences and the ironic nature of randomized trials. Med Decis Making 2011;31(2):226-228
83. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. Hyattsville,MD: National Center for Health Statistics, 2009. NCHS Data Brief, no. 22
84. Webster LR, Cochella S, Dasgupta N, et al. An analysis of root causes for opioid-related overdose deaths in the United States. Pain Med 2011;12:S26-S35
85. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999;94(7):961-972
86. Winstock A, Sheridan J, Lovell S, et al. Availability of overdose resuscitation facilities: a survey of drug agencies in England and Wales. J Subst Use 2000;5:99-102
87. Wolff K. Characterization of methadone overdose: clinical considerations and the scientific evidence. Ther Drug Monit 2002;24(4):457-470
88. Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction 2000;95(1):77-84
89. Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence: a current perspective.West J Med 1990;152:588-599